Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 Mar;165(3):657-663.
doi: 10.1016/j.surg.2018.09.008. Epub 2018 Oct 28.

Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection

Affiliations
Multicenter Study

Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection

Charles W Kimbrough et al. Surgery. 2019 Mar.

Abstract

Background: The incidence, clinical characteristics, and long-term outcomes of patients with gastroenteropancreatic neuroendrocrine tumors and carcinoid syndrome undergoing operative resection have not been well characterized.

Methods: Patients undergoing resection of primary or metastatic gastroenteropancreatic neuroendrocrine tumors between 2000 and 2016 were identified from an 8-institution collaborative database. Clinicopathologic and postoperative characteristics as well as overall survival and disease-free survival were compared among patients with and without carcinoid syndrome.

Results: Among 2,182 patients who underwent resection, 139 (6.4%) had preoperative carcinoid syndrome. Patients with carcinoid syndrome were more likely to have midgut primary tumors (44.6% vs 21.4%, P < .001), lymph node metastasis (63.4% vs 44.3%, P < .001), and metastatic disease (62.8% vs 26.7%, P < .001). There was no difference in tumor differentiation, grade, or Ki67 status. Perioperative carcinoid crisis was rare (1.6% vs 0%, P < .01), and the presence of preoperative carcinoid syndrome was not associated with postoperative morbidity (38.8% vs 45.5%, P = .129). Substantial symptom improvement was reported in 59.5% of patients who underwent curative-intent resection, but occurred in only 22.7% who underwent debulking. Despite an association on univariate analysis (P = .04), carcinoid syndrome was not independently associated with disease-free survival after controlling for confounding factors (hazard ratio 0.97, 95% confidence interval 0.64-1.45). Preoperative carcinoid syndrome was not associated with overall survival on univariate or multivariate analysis.

Conclusion: Among patients undergoing operative resection of gastroenteropancreatic neuroendrocrine tumors, the prevalence of preoperative carcinoid syndrome was low. Although operative intervention with resection or especially debulking in patients with carcinoid syndrome was disappointing and often failed to improve symptoms, after controlling for markers of tumor burden, carcinoid syndrome was not independently associated with worse disease-free survival or overall survival.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Kaplan-Meier analysis of (A) disease-free survival after complete macroscopic resection (R0/R1 patients) and (B) overall survival of all patients with and without carcinoid syndrome.

Similar articles

Cited by

  • Surgical management of pancreatic neuroendocrine liver metastases.
    Cloyd JM, Wiseman JT, Pawlik TM. Cloyd JM, et al. J Gastrointest Oncol. 2020 Jun;11(3):590-600. doi: 10.21037/jgo.2019.11.02. J Gastrointest Oncol. 2020. PMID: 32655938 Free PMC article. Review.
  • Carcinoid Syndrome: Preclinical Models and Future Therapeutic Strategies.
    Vitale G, Carra S, Alessi Y, Campolo F, Pandozzi C, Zanata I, Colao A, Faggiano A, On Behalf Of The Nike Group. Vitale G, et al. Int J Mol Sci. 2023 Feb 10;24(4):3610. doi: 10.3390/ijms24043610. Int J Mol Sci. 2023. PMID: 36835022 Free PMC article. Review.
  • NT-proBNP as a neuroendocrine tumor biomarker: beyond heart failure.
    Komarnicki P, Gut P, Musiałkiewicz J, Cieślewicz M, Maciejewski A, Patel P, Mastorakos G, Ruchała M. Komarnicki P, et al. Endocr Connect. 2023 Sep 13;12(10):e230249. doi: 10.1530/EC-23-0249. Print 2023 Oct 1. Endocr Connect. 2023. PMID: 37552533 Free PMC article.
  • Consensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms.
    Su DG, Brown LM, Bansal VV, Bakkila B, Concors SJ, Turaga KK, Gunderson C, Bergsland E, Strosberg JR, Halfdanarson TR, Metz DC, Kunstman JW, Kunz PL, Gangi A; Peritoneal Surface Malignancies (PSM) Consortium Group. Su DG, et al. Ann Surg Oncol. 2025 Jun 25. doi: 10.1245/s10434-025-17360-3. Online ahead of print. Ann Surg Oncol. 2025. PMID: 40560496
  • Gender-related differences in patients with carcinoid syndrome: new insights from an Italian multicenter cohort study.
    Ruggeri RM, Altieri B, Razzore P, Retta F, Sperti E, Scotto G, Brizzi MP, Zumstein L, Pia A, Lania A, Lavezzi E, Nappo G, Laffi A, Albertelli M, Boschetti M, Hasballa I, Veresani A, Prinzi N, Pusceddu S, Oldani S, Nichetti F, Modica R, Minotta R, Liccardi A, Cannavale G, Grossrubatscher EM, Tarsitano MG, Zamponi V, Zatelli MC, Zanata I, Mazzilli R, Appetecchia M, Davì MV, Guarnotta V, Giannetta E, La Salvia A, Fanciulli G, Malandrino P, Isidori AM, Colao A, Faggiano A; NIKE Group. Ruggeri RM, et al. J Endocrinol Invest. 2024 Apr;47(4):959-971. doi: 10.1007/s40618-023-02213-1. Epub 2023 Oct 14. J Endocrinol Invest. 2024. PMID: 37837555 Free PMC article.

References

    1. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342. - PMC - PubMed
    1. Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18:525–534. - PMC - PubMed
    1. Cai B, Broder MS, Chang E, et al. Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors. World J Gastroenterol. 2017;23:7283–7291. - PMC - PubMed
    1. Ito T, Igarashi H, Nakamura K, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol. 2015;50:58–64. - PubMed
    1. Soga J. Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases. J Exp Clin Cancer Res. 2003;22:517–530. - PubMed

Publication types

MeSH terms

Supplementary concepts